 Connection
David Raben to Prognosis
This is a "connection" page, showing publications David Raben has written about Prognosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.516 |
|
|
|
-
Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018 10 15; 24(20):4949-4959.
Score: 0.083
-
O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA, Adelstein D, Burkey BB, Friborg J, Kristensen CA, Gothelf AB, Hoebers F, Kremer B, Speel EJ, Bowles DW, Raben D, Karam SD, Yu E, Xu W. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016 04; 17(4):440-451.
Score: 0.071
-
Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009 Apr; 32(2):115-21.
Score: 0.044
-
Vega DM, Nishimura KK, Zariffa N, Thompson JC, Hoering A, Cilento V, Rosenthal A, Anagnostou V, Baden J, Beaver JA, Chaudhuri AA, Chudova D, Fine AD, Fiore J, Hodge R, Hodgson D, Hunkapiller N, Klass DM, Kobie J, Pe?a C, Pennello G, Peterman N, Philip R, Quinn KJ, Raben D, Rosner GL, Sausen M, Tezcan A, Xia Q, Yi J, Young AG, Stewart MD, Carpenter EL, Aggarwal C, Allen J. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. JCO Precis Oncol. 2022 08; 6:e2100372.
Score: 0.028
-
Hernandez AL, Young CD, Bian L, Weigel K, Nolan K, Frederick B, Han G, He G, Devon Trahan G, Rudolph MC, Jones KL, Oweida AJ, Karam SD, Raben D, Wang XJ. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clin Cancer Res. 2020 06 15; 26(12):3058-3070.
Score: 0.023
-
Fakhry C, Zhang Q, Gillison ML, Nguyen-T?n PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Yom SS, Wong SJ, Ridge JA, Rao SSD, Spencer S, Fortin A, Raben D, Harris J, Le QT. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials. Cancer. 2019 06 15; 125(12):2027-2038.
Score: 0.022
-
Ding D, Stokes W, Eguchi M, Hararah M, Sumner W, Amini A, Goddard J, Somerset H, Bradley C, McDermott J, Raben D, Karam SD. Association Between Lymph Node Ratio and Recurrence and Survival Outcomes in Patients With Oral Cavity Cancer. JAMA Otolaryngol Head Neck Surg. 2019 01 01; 145(1):53-61.
Score: 0.022
-
Robin TP, Raben D, Schefter TE. A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management. Semin Radiat Oncol. 2018 10; 28(4):288-294.
Score: 0.021
-
Fakhry C, Zhang Q, Nguyen-T?n PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol. 2017 Dec 20; 35(36):4057-4065.
Score: 0.020
-
Sumner WA, Stokes WA, Oweida A, Berggren KL, McDermott JD, Raben D, Abbott D, Jones B, Gan G, Karam SD. Survival impact of pre-treatment neutrophils on oropharyngeal and laryngeal cancer patients undergoing definitive radiotherapy. J Transl Med. 2017 08 02; 15(1):168.
Score: 0.020
-
Robin TP, Jones BL, Gordon OM, Phan A, Abbott D, McDermott JD, Goddard JA, Raben D, Lanning RM, Karam SD. A comprehensive comparative analysis of treatment modalities for sinonasal malignancies. Cancer. 2017 Aug 15; 123(16):3040-3049.
Score: 0.019
-
Stokes WA, Amini A, Jones BL, McDermott JD, Raben D, Ghosh D, Goddard JA, Bowles DW, Karam SD. Survival impact of induction chemotherapy in advanced head and neck cancer: A National Cancer Database analysis. Head Neck. 2017 06; 39(6):1113-1121.
Score: 0.019
-
Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The?RTOG Experience. Int J Radiat Oncol Biol Phys. 2016 08 01; 95(5):1346-1354.
Score: 0.018
-
Dan TD, Raben D, Schneider CJ, Hockstein NG, Witt RL, Dzeda M, Cormier JF, Raben A. Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-positive tonsil cancer: updated results of an institutional clinical management approach. Oral Oncol. 2015 Jun; 51(6):616-21.
Score: 0.017
-
Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 2014 Dec 10; 32(35):3930-8.
Score: 0.016
-
Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urol Oncol. 2015 Feb; 33(2):71.e11-9.
Score: 0.016
-
Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol. 2014 Jul; 32(5):707-13.
Score: 0.015
-
Carlson J, Licitra L, Locati L, Raben D, Persson F, Stenman G. Salivary gland cancer: an update on present and emerging therapies. Am Soc Clin Oncol Educ Book. 2013; 257-63.
Score: 0.014
-
Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008 May 17; 371(9625):1695-709.
Score: 0.010
-
Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 2008 Jan 15; 112(2):345-51.
Score: 0.010
-
Rabinovitch R, Grant B, Berkey BA, Raben D, Ang KK, Fu KK, Cooper JS. Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: a secondary analysis of RTOG trial 90-03. Head Neck. 2006 Apr; 28(4):287-96.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|